



RepliCel™

Using Cells for Healing


OTCQB: REPCF | TSXV: RP | FRA:P6P2

COMPANY PROFILE Q2 2019

A Revolution in Sports Medicine and Aesthetics.

We are a regenerative medicine company with innovative cell therapy technology providing unparalleled skin rejuvenation, tendon regeneration, and hair regrowth.

Three applications, two biologics, one game-changing delivery platform



RCI-02 PATENTED DERMAL INJECTION DEVICE

The RCI-02 dermal injector is designed to deliver cells, dermal fillers, drug and biologics.

- Digital controls program for depth, volume, rate of dispersion
- Provides exact repeatable dispersion across 3 dimensions
- Removes human variability
- Built-in Peltier element reduces need for anesthetics
- Near-term commercial launch

Poised for growth and momentum

Potential to Revolutionize Sports Medicine and Aesthetics

This innovative cell therapy technology has the potential to revolutionize two large consumer-pay markets where few solutions exist.

The Only Regenerative Medicine Company Using Hair Follicle Cell Therapy

We are the only Company using cells derived from hair follicles to potentially heal damaged skin and tendon tissue—offering hope for people with conditions beyond repair.

Multiple Assets Addressing Conditions With Unmet Need

Multi-product portfolio diversifies risk over several programs in two different markets.

Near-Term Commercial Launch And Revenue Catalysts

Anticipated approval to commercially launch the dermal injector in Europe and Hong Kong by mid-2020 in Europe and Hong Kong. Hair regrowth product could be launched in Japanese market by Shiseido as early as 2020.

Multiple Assets Across Large Market Applications with Key Partnership in Place

Positive phase I clinical data and dermal injector prototypes focused on skin, tendon and hair health (all large markets).

Management Is Commercially-Focused And Strategic

Focus is on leveraging partnership programs and preparing for commercial product launch.

Capital Structure (as at May 2019)

Current market cap. (approx.)	~\$10M
Total money raised through equity to-date	~\$34M
Total revenue to-date (upfront licensing payments)	\$4.24M
Current Monthly Burn Rate	~\$259,000
Shares Issued and Outstanding (Basic/FD)	27.6M / 33.5M

Board and Management Team

David Hall
Chairman

Directors:

Peter Lowry

Andrew Schutte

Peter Lewis

Lee Buckler

Larissa Huang

R. Lee Buckler, B. Ed, LLB
President, CEO & Director

Dr. Rolf Hoffman, MD
Chief Medical Officer

Dr. Kevin McElwee, PhD Chief
Scientific Officer

Simon Ma CA
Chief Financial Officer

Petra Goessens-Rueck, DVM
Head of Clinical and Regulatory Affairs